Propel Contour (sinusitis implant)

2021: Implant announcement for sinusitis treatment

At the end of May 2021, the American company Intersect ENT Menlo Park announced the release of the Propel Contour nose sinus implant, designed to treat chronic sinusitis. It improves the patency of the nasal passages and reduces inflammation by keeping the mouth of the sinuses of the nose open by mechanically supporting and releasing corticosteroids.

Propel Contour is the third local drug release implant in the family of bioabsorbable implants developed by Intersect ENT. The implant has the shape of an hourglass and is intended for installation into frontal sinuses after ENT surgery in patients with chronic rhinosinusitis. The implant also includes a low profile flexible drug administration system that facilitates access to the mouth of the frontal sinus.

Propel Contour (sinusitis implant)

The release of the devices was authorized after receiving favorable treatment results as part of a clinical study of 80 patients in the United States. The study reached a major efficacy endpoint: the Propel Contour cohort noted a statistically significant 65% reduction in the need for postoperative interventions, including a need for additional surgical procedures or a need for oral corticosteroid prescribing. During clinical studies, Intersect ENT did not reveal serious side effects associated with implants.

We are pleased that Propel Contour, the latest addition to the Propel family of nasal sinus steroid-releasing implants, is now available in some EU countries to treat patients undergoing nasal sinus surgery as part of chronic rhinosinusitis therapy, said Thomas A. West, President and CEO of Intersect ENT. - Our goal is to offer doctors a wide range of products that will allow them to choose treatment for each patient.[1]

Notes